PubMed Health⌕ Search

PubMed · 14633786

Molecular diagnostics.

Abstract

It is increasingly evident that molecular diagnostics, that is, the use of diagnostic testing to understand the molecular mechanisms of an individual patient's disease, will be pivotal in the delivery of safe and effective therapy for many diseases in the future. A huge body of new information on the genetic, genomic and proteomic profiles of different hematopoietic diseases is accumulating. This chapter focuses on new technologies and advancements in understanding the molecular basis of hematologic disorders, providing an overview of new information and its significance to patient care. In Section I, Dr. Braziel discusses the impact of new genetic information and research technologies on the actual practice of diagnostic molecular hematopathology. Recent and projected changes in methodologies and analytical strategies used by clinical molecular diagnostics laboratories for the evaluation of hematologic disorders will be discussed, and some of the challenges to clinical implementation of new molecular information and techniques will be highlighted. In Section II, Dr. Shipp provides an update on current scientific knowledge in the genomic profiling of malignant lymphomas, and describes some of the technical aspects of gene expression profiling. Analysis methods and the actual and potential clinical and therapeutic applications of information obtained from genomic profiling of malignant lymphomas are discussed. In Section III, Dr. Liotta presents an update on proteomic analysis, a new and very active area of research in hematopoietic malignancies. He describes new technologies for rapid identification of different important proteins and protein networks, and the potential therapeutic and prognostic value of the elucidation of these proteins and protein pathways in the clinical care of patients with malignant lymphomas.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rita M Braziel, Margaret A Shipp, Andrew L Feldman, Virginia Espina, Mary Winters, Elaine S Jaffe, Emanuel F Petricoin, Lance A Liotta. 2003. Molecular diagnostics.. https://doi.org/10.1182/asheducation-2003.1.279

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings.

The NF2 tumor suppressor gene on chromosome 22 is a member of the protein 4.1 family of cytoskeletal elements. A number of single- and multiple-tumor phenotypes have been linked to alterations of NF2 since its characterization in 1993. We present a meta-analysis of 967 constitutional and somatic NF2 alterations from 93 published reports, along with 59 additional unpublished events identified in our laboratory and 115 alterations identified in clinical samples submitted to the Massachusetts General Hospital (MGH) Neurogenetics DNA Diagnostic Laboratory. In total, these sources defined 1,070 small genetic changes detected primarily by exon scanning, 42 intragenic changes of one whole exon or larger, and 29 whole gene deletions and gross chromosomal rearrangements. Constitutional single-exon events (N=422) were significantly more likely to be nonsense or splice site changes than somatic events (N=533), which favored frameshift changes (chi(2) test; P<0.001). Somatic events also differed markedly between tumors of different pathology, most significantly in the tendency of somatic events in meningiomas to lie within the 5' FERM domain of the transcript (Fisher's exact test; P<0.01 in comparison to schwannomas) with a complete absence of mutations in exons 14 and 15. There was no statistically significant difference in mutation type or exon distribution between published constitutional events and those found by the clinical laboratory. Less than 10% of all published and unpublished small alterations are nontruncating (N=63) and these changes are clustered in exons 2 and 3, suggesting that this region may be especially crucial to tumor suppressor activity in the protein.

Cytogenetic Analysis↗

Presenting statistical uncertainty on cytogenetic dose estimates.

Cytogenetic dosimetry results are customarily accompanied by 95% confidence limits and the derivation of these limits is discussed. Simply presenting values of the best estimate of dose and 95% limits assumes that recipients of dosimetry reports, possibly the patients themselves, have a sufficient grasp of statistics to comprehend the concept of uncertainty. Two further methods have been developed to aid improved understanding for the lay person. The first method, particularly useful for suspected low doses, presents a simple odds ratio indicating that the results favour either zero dose or that suspected; for example, from an unexpected dose recorded on a badge. The second method, described fully here for the first time, uses a graphical illustration of a normalised distribution of dose so that one may visualise the area beneath a curve that represents the probability that the dose lies within various bounds.

Cytogenetic Analysis↗